Age‑related macular degeneration (AMD) is a degenerative disease of the central retina, which leads to a serious reduction in visual acuity. The pathogenesis of the disease is not fully understood, and assumed to be multifactorial. AMD occurs in two clinical types: nonexudative, dry form (geographic atrophy and/or drusen) and exudative, wet form (subretinal neovascular membrane). Currently, numerous studies are conducted on the development of effective treatment of neovascular AMD. The gold standard for the treatment of the wet AMD is intravitreal administration of anti‑angiogenic drugs. Drugs are being developed that could be given in the form of implant and enable sustained release of the active substance, therefore reducing the need for frequent interventions. Ongoing studies on the analysis of disturbed metabolic pathways and genes that modulate progression of the disease would enable implementation of the targeted therapy. Attempts to treat the exudative form of AMD are not limited to injectable medications applied to the vitreous body. A search for a new, effective form of treatment is also focused at the surgical and laser intervention possibilities.